药渡经纬信息科技（北京）有限公司

What 药渡经纬信息科技（北京）有限公司 does

Pharmacodia (药渡经纬信息科技（北京）有限公司) is a Beijing-based, privately held pharmaceutical data and consulting company founded in 2017. It operates a multi-module platform serving Chinese biopharmaceutical companies, biotech firms, investment institutions, and industrial parks. Core offerings include 药渡数据 (Pharmacodia Data), a global drug and medical device competitive intelligence platform with a knowledge graph spanning 30,000+ biological/chemical drugs, 750,000+ approved/registered products, and 26,000,000+ patents and literature entries; 企业洞察 (Enterprise Insights), tracking 100,000+ medical enterprises, 10,000+ investment institutions, and 20,000+ financing events; 药渡咨询 (Pharmacodia Consultancy), a one-stop consulting service covering strategic consulting, project due diligence, product evaluation, patent services, market research, and bio-pharma park services; CyberAIDD/CyberSAR, an AI-driven drug design module applying structure-activity relationship analysis; 渡选CXO, a CXO service provider matchmaking platform; 全球器械 (Global Devices), medical device competitive intelligence; and 数据定制 (Data Customization), bespoke data extraction services. Customer logos include large Chinese pharma (NHWA Group, Luye Pharma, Yangzijiang Pharmaceutical, Beilu Pharma), biotech (AcroBiosystems, Beta Pharma), Jinan University, and tier-1 financial institutions (Ping An Bank, CMS China, GTJA, Yingke PE).

The company generates revenue through two primary streams: (1) subscription/recurring access to web-based data platforms (drug, device, enterprise insights, and AI tools), and (2) professional consulting services delivered through direct enterprise engagement. Distribution is primarily self-service web (PLG) for data subscriptions, augmented by a direct field sales motion with dedicated business cooperation and customer service contacts for larger enterprise and consulting contracts. Pricing is quote-based and not publicly disclosed; the company is headquartered in Beijing with a reported 54 employees and no disclosed institutional investors, suggesting founder/self-financed growth to date.

Underlying technology combines curated and aggregated pharmaceutical, regulatory, patent, and enterprise data with knowledge-graph presentation, SAR-based computational chemistry for AI-aided design, and proprietary consulting methodologies developed through what the company describes as over 2 billion RMB in value assessment transaction volume and 25+ patent due diligence families. The architecture is best characterized as a vertical life-sciences data and intelligence platform rather than a primary AI or SaaS infrastructure play, with AI capabilities featured in one product module but not foundational across the business.

Name

药渡经纬信息科技（北京）有限公司

Legal name

药渡经纬信息科技（北京）有限公司

Website

https://pharmacodia.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

Pharmacodia (药渡经纬) is a Beijing-based pharmaceutical data and consulting company that operates a multi-module platform covering global drug and medical device intelligence, enterprise and investment insights, AI-aided drug design, and one-stop consulting services for Chinese pharma, biotech, investment institutions, and industrial parks.

Ownership category

akta.pro rank

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Data Platform Subscription: Access to drug data, enterprise insights, medical device data, and AI-driven drug design tools through web-based subscription model.
2. Consulting Services: Professional consulting services including strategic consulting, project due diligence, patent services, product launch services, industry research, and training. These are one-stop consulting services connecting capital markets with the market.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

药渡经纬信息科技（北京）有限公司 operates a pharmaceutical big data and consulting services business serving the Chinese biopharmaceutical industry. Its core offering combines subscription-based web platforms — 药渡数据 (global drug and device competitive intelligence with knowledge graph), 企业洞察 (enterprise and investment intelligence), CyberAIDD (AI-driven new drug design) — with professional consulting services spanning strategic consulting, project due diligence, product evaluation, patent services, market research, and bio-pharma park advisory.

Product overview

药渡经纬信息科技（北京）有限公司 operates a multi-module platform for the Chinese biopharmaceutical industry, centered around 药渡数据 (Pharmacodia Data) as the core intelligence platform, supplemented by specialized modules including CyberAIDD for AI-powered drug design, 企业洞察 for company/investment intelligence, 渡选CXO for service provider connections, and 药渡咨询 for professional consulting services. The platform covers pharmaceutical drugs, medical devices, patents, literature, and enterprise financing data.

Differentiator

Problem solved

Functional benefit

Brands

• 药渡数据: Global pharmaceutical and medical device competitive intelligence platform with knowledge graph capabilities
• 药渡咨询
• CyberAIDD
• CyberSAR
• 渡选CXO

Products and services

• 药渡数据 (Pharmacodia Data) Global pharmaceutical and medical device competitive intelligence platform featuring a knowledge graph; covers 30,000+ biological/chemical drugs, 750,000+ approved/registered products, and 26,000,000+ patents and literature entries for pharmaceutical R&D and competitive intelligence users.
• 药渡咨询 (Pharmacodia Consulting) One-stop professional consulting service covering strategic consulting, project due diligence, product evaluation, patent analysis, market research, product launch services, training, and bio-pharmaceutical park advisory for the Chinese biopharmaceutical industry.
• CyberAIDD (with CyberSAR) AI-driven new drug design platform featuring CyberSAR structure-activity relationship analysis for accelerated drug discovery and development, targeting pharmaceutical R&D teams.
• 企业洞察 (Enterprise Insights) Company intelligence platform tracking 100,000+ medical enterprises, 10,000+ investment institutions, and 20,000+ financing events for investment and business development purposes.
• 全球器械 (Global Devices) Global medical device data platform providing competitive intelligence and regulatory information for medical devices, complementing the drug data module.
• 渡选CXO (CXO Services) CXO service platform connecting pharmaceutical companies with contract research and executive service providers, enabling buyers to source CXO capabilities.
• 数据定制 (Data Customization / Open Data) Customized pharmaceutical data services that allow clients to request specific data sets and tailored information solutions beyond standard platform access.

Quantifiable outcome

• 2,000,000,000,000+ RMB value assessment transaction volume processed
• +2 more outcomes

Named customers12 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• EvaluatePharma (Norstella): Pharmaceutical market intelligence platform providing forecasts, deal analytics and pipeline valuations for pharma and investors. Overlaps with Pharmacodia's Enterprise Insights and consulting modules on valuation, deal sourcing and competitive landscape analytics.
• Patsnap (智慧芽): China-based IP, patent and innovation intelligence platform serving R&D, legal and investment teams. Highly comparable to Pharmacodia as a Chinese-headquartered data subscription + analytics platform combining patent/literature mining with enterprise intelligence.
• China Insights Consultancy (CIC): China-based market research, consulting and industry intelligence firm with deep coverage of healthcare, pharma and consumer industries. Comparable to Pharmacodia on Chinese biopharma strategic consulting, industry research and due diligence for capital markets clients.
• PharmCube (药融云): China-based pharma data and industry intelligence platform covering pipelines, registrations, clinical trials and investment activity for the biopharma sector. The most direct domestic competitor to Pharmacodia across drug data, enterprise intelligence and investor analytics.

Emerging players

• DrugBank: Drug-focused biochemical and pharmacological database widely used in pharma R&D and AI drug discovery. Comparable to Pharmacodia's drug database as a subscription knowledge asset for drug R&D, though narrower in scope (drug-only, no enterprise/financing data).

Broad incumbents

• Clarivate (Cortellis): Global IP, drug and regulatory intelligence provider offering Cortellis and the Derwent patent suite. Direct overlap with Pharmacodia on drug, patent and competitive intelligence workflows, with a much broader international footprint.
• GlobalData: Global market intelligence provider with a large pharma and healthcare industry research offering. Comparable to Pharmacodia on consulting-grade market research and forecasts for pharma/biotech, with established international coverage.
• WuXi AppTec (药明康德): China-headquartered contract research, development and manufacturing organization serving global pharma. Comparable as a flagship Chinese life-sciences platform, though operating in laboratory services rather than data/AI; both anchor the Chinese biopharma ecosystem.
• IQVIA: Global life sciences data, analytics and clinical research services giant. Comparable via its pharma market intelligence, R&D data subscriptions and AI-driven commercial analytics, but operates at vastly larger scale across pharma and biotech globally.
• Norstella / Citeline (formerly Pharma Intelligence, Informa): Global pharma and clinical intelligence provider (parent of Citeline, Evaluate, PharmaProjects, Trialtrove) serving pharma, biotech and investors. Comparable to Pharmacodia on pipeline and clinical intelligence, but at vastly larger scale with deeper international coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/yaodu

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 药渡经纬信息科技（北京）有限公司